Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: NeoPath v. Neuromedical Systems Inc.

This article was originally published in The Gray Sheet

Executive Summary

NeoPath v. Neuromedical Systems Inc.: NeoPath files suit March 28 in the U.S. District Court for the Western District of Washington in Seattle alleging that Neuromedical's Papnet automated cervical cytology reader system infringes three NeoPath patents covering technology utilized in its AutoPap 300 QC Pap smear slide quality control rescreening system. The suit requests that the court grant "preliminary and final injunctions enjoining" Neuromedical and its subsidiaries from further infringement and "award damages in the amount of lost profits for the infringement of" the three patents. Neuromedical plans to contest the suit. A separate suit filed in July by Neuromedical Systems against NeoPath makes several allegations, including patent infringement, false advertising and unfair competition ("The Gray Sheet" July 22, 1996, In Brief)...

You may also be interested in...



QUOTED. 27 November 2020. Agam Sharda.

The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel